Wegovy for NASH: What Women Need to Know About This Off-Label Use

What Does "Off-Label" Mean for Wegovy and NASH?

Wegovy (semaglutide 2.4 mg) received FDA approval in June 2021 for chronic weight management in adults with a BMI of 30 or above, or BMI of 27 or above with at least one weight-related comorbidity. In March 2024, the FDA expanded that label to include reducing cardiovascular events in adults with obesity and established cardiovascular disease. NASH (nonalcoholic steatohepatitis) is not on either label.

Off-label prescribing is legal and common in the United States. A clinician can prescribe any approved drug for any condition where clinical judgment supports it. What off-label status means for you in practice: insurance coverage is far less likely, and the prescribing physician carries greater responsibility for explaining the evidence base.

For NASH specifically, the off-label use of Wegovy sits on genuinely solid ground, much more so than most off-label prescribing decisions. Phase 3 randomized controlled trial data now exists, which is more evidence than many FDA-approved treatments ever accumulate before approval.

What Is NASH and Why Do Women Face a Distinct Risk?

NASH is a progressive form of fatty liver disease characterized by inflammation and hepatocyte injury on top of fat accumulation. Without treatment, it can progress to cirrhosis, liver failure, and hepatocellular carcinoma. Approximately 1.5-6.5% of the global population has NASH, and prevalence is rising in parallel with obesity and type 2 diabetes rates.

PCOS and NASH

Women with polycystic ovary syndrome carry a substantially elevated NASH risk. A 2016 meta-analysis published in Human Reproduction Update found that women with PCOS have a 2-3 times higher odds of NAFLD compared with matched controls, independent of BMI. The mechanism involves hyperinsulinemia, androgen excess, and visceral adiposity, all of which drive hepatic lipid accumulation. If you have PCOS and have been told your liver enzymes are elevated, a formal NASH evaluation is warranted.

Perimenopause, Menopause, and the Liver

Estrogen has a protective effect on hepatic lipid metabolism. As estrogen declines during perimenopause, women experience a shift toward visceral fat deposition and worsening insulin sensitivity. A 2023 analysis in Hepatology reported that postmenopausal women have significantly higher rates of advanced liver fibrosis compared with premenopausal women with equivalent metabolic profiles. This means NASH can accelerate in your 40s and 50s in ways that differ from what happens in men of the same age, and from what happened to you earlier in life.

Reproductive-Age Women

In reproductive-age women without PCOS, NASH prevalence is historically lower than in men of the same age. This sex difference narrows significantly after menopause. One implication: a woman who is diagnosed with NASH before age 40 should prompt clinicians to look carefully for PCOS, hypothyroidism, or another underlying driver rather than attributing it to obesity alone.

The Clinical Trial Evidence: ESSENCE and Earlier Data

The ESSENCE Phase 3 Trial

The most significant evidence for semaglutide in NASH comes from the ESSENCE trial, published in The New England Journal of Medicine in 2024. ESSENCE was a multicenter, double-blind, placebo-controlled phase 3 trial enrolling 800 adults with biopsy-confirmed NASH and stage F2 or F3 fibrosis. Participants were randomized to semaglutide 2.4 mg once weekly or placebo for 72 weeks, with liver biopsy at baseline and end of treatment.

The primary endpoints were:

• NASH resolution without worsening fibrosis
• Fibrosis improvement of at least one stage without NASH worsening

Results on the first primary endpoint: 62.9% of patients on semaglutide achieved NASH resolution without fibrosis worsening, compared with 34.3% on placebo (p <0.001). On the second endpoint, fibrosis improved by at least one stage in 36.8% of semaglutide participants versus 22.4% on placebo (p <0.001). These are the largest histological response rates reported in any NASH trial to date.

Sex-disaggregated subgroup data from ESSENCE have not been published in full as of this writing. Women represented approximately 54% of the trial population, which is an unusually high female enrollment for a metabolic disease trial and a meaningful step toward filling the evidence gap described below.

The Phase 2 Semaglutide NASH Trial (2021)

Before ESSENCE, a phase 2 trial published in The New England Journal of Medicine in 2021 enrolled 320 adults with biopsy-confirmed NASH. At the 0.4 mg dose (lower than the 2.4 mg Wegovy dose), 59% of patients receiving semaglutide achieved NASH resolution, compared with 17% on placebo. Fibrosis improvement rates did not reach statistical significance in this smaller trial, which made the ESSENCE fibrosis results all the more meaningful.

The Evidence Gap for Women

Women have been historically underrepresented in liver disease clinical trials. Most foundational NASH studies were conducted with male-majority enrollment, and treatment response data are rarely reported by sex. What we know about semaglutide's hepatic effects in women largely comes from ESSENCE's aggregate results and post-hoc subgroup analyses. We do not yet have high-quality head-to-head data comparing response rates between premenopausal, perimenopausal, and postmenopausal women. This gap is worth naming plainly: the strong aggregate results from ESSENCE are encouraging, but they should not be taken as proof that all women respond equally regardless of hormonal status.

How Semaglutide Works in the Liver: Sex-Relevant Mechanisms

Semaglutide is a GLP-1 receptor agonist. Its hepatic effects arise through several pathways that are worth understanding, particularly as they interact with female physiology.

Weight Loss and Hepatic Fat

The most direct mechanism is weight-dependent. A 10% reduction in body weight produces clinically meaningful decreases in hepatic steatosis and inflammation, and semaglutide 2.4 mg produces average weight loss of approximately 15-17% in trials like STEP 1. Women in the STEP 1 trial lost an average of 14.9% of body weight at 68 weeks, comparable to men, though the absolute kilogram loss differed due to baseline body composition differences.

Weight-Independent Effects

GLP-1 receptors are expressed in hepatocytes, and preclinical data suggest direct anti-inflammatory and anti-fibrotic effects independent of weight loss. Whether these weight-independent pathways are clinically meaningful in humans at the 2.4 mg dose remains an active research question, and the current evidence does not allow firm conclusions.

Insulin Sensitivity

Improved insulin sensitivity is a central mechanism relevant for women with PCOS or perimenopausal insulin resistance. Hyperinsulinemia drives de novo lipogenesis in the liver. Semaglutide reduces fasting insulin and HOMA-IR substantially, which may be particularly valuable for the PCOS-related NASH phenotype.

Pregnancy, Lactation, and Contraception: Non-Negotiable Safety Information

Wegovy is contraindicated in pregnancy. This is not a relative contraindication. The FDA label carries a clear warning: semaglutide caused fetal harm in animal reproduction studies, and the drug should be discontinued at least 2 months before a planned pregnancy. The 2-month washout period reflects the drug's approximately 4-week half-life and provides a safety margin.

Human pregnancy data are limited. A 2024 pharmacovigilance review identified case reports of semaglutide exposure in early pregnancy, but systematic human teratogenicity data do not exist. Given animal data showing fetal growth restriction and structural anomalies at clinically relevant exposures, the risk-benefit ratio clearly favors stopping treatment before conception.

If You Are Trying to Conceive

Women with NASH who are also trying to conceive face a real clinical tension. NASH itself worsens pregnancy outcomes, including risk of gestational hypertension and preterm birth. Treating NASH before pregnancy is a legitimate goal, but semaglutide cannot be the tool during the attempt. Your clinician can discuss timeline: treat with semaglutide, achieve liver histology improvement, stop the drug at least 2 months before trying, and then proceed. This sequence is not formally studied but is mechanistically reasonable.

Lactation

No human lactation data exist for semaglutide. Given the high molecular weight of the peptide, transfer into breast milk may be low, but this has not been measured in lactating women. The manufacturer advises against use during breastfeeding. Decisions for individual women should involve shared decision-making with their clinician.

Contraception Requirements

Because semaglutide is teratogenic in animals and must be stopped before pregnancy, women of reproductive age using Wegovy for NASH off-label should use reliable contraception throughout treatment. Oral contraceptives have not been shown to have meaningfully altered absorption with semaglutide, but the GI effects of semaglutide (nausea, vomiting, slowed gastric emptying) may theoretically reduce oral contraceptive absorption during dose escalation. ACOG guidance on contraception with GLP-1 agents is evolving; a barrier method or IUD during the first 4-8 weeks of dose escalation is a practical precaution.

Who This Is Right For, and Who Should Not Use It

Not every woman with NASH is an appropriate candidate for off-label Wegovy. The decision involves weighing evidence quality, individual risk profile, and practical access.

Women Who May Benefit Most

• Women with biopsy-confirmed NASH at fibrosis stage F2 or F3 who have not achieved adequate improvement with 6-12 months of sustained lifestyle modification
• Women with PCOS plus NASH, given the overlapping metabolic phenotype that GLP-1 agents address well
• Perimenopausal or postmenopausal women with NASH and insulin resistance, where estrogen loss has accelerated metabolic dysfunction
• Women with NASH plus type 2 diabetes or prediabetes, where the glycemic and hepatic benefits converge
• Women with a BMI of 27 or above (the weight management label threshold) who also have confirmed NASH

Women for Whom Wegovy Is Not Appropriate

• Pregnant women or those planning pregnancy within 2 months
• Women with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN 2), due to thyroid C-cell tumor signal seen in rodent studies
• Women with severe gastroparesis or a history of pancreatitis
• Women with advanced cirrhosis (Child-Pugh B or C): ESSENCE enrolled F2/F3 fibrosis only. Data in decompensated liver disease are absent.
• Women with NASH at fibrosis stage F0-F1 who respond to lifestyle intervention: the risk-benefit calculation shifts when disease is mild and reversible by other means

Practical Prescribing Considerations for Off-Label Use

Dosing and Titration

The dose studied in ESSENCE is semaglutide 2.4 mg subcutaneous once weekly, which is the Wegovy formulation. Ozempic (semaglutide up to 2.0 mg for type 2 diabetes) is a different label at a slightly lower top dose, though some clinicians use it interchangeably. The standard Wegovy titration schedule starts at 0.25 mg weekly for 4 weeks and escalates every 4 weeks to reach 2.4 mg by week 16-20.

Women tend to report GI side effects (nausea, vomiting, constipation) at higher rates than men across GLP-1 trials. Slower titration, specifically extending each dose step from 4 weeks to 6-8 weeks if nausea is significant, is a reasonable clinical approach not contraindicated by the label.

Monitoring in Women with NASH on Semaglutide

A monitoring framework for this off-label indication should include:

• Liver function tests (ALT, AST, GGT) at baseline and every 3 months for the first year
• Fasting glucose and HbA1c at baseline and every 6 months
• FibroScan (transient elastography) at baseline and at 12 months to assess fibrosis response non-invasively
• Repeat liver biopsy at 72 weeks if the clinical decision hinges on histological confirmation, as in ESSENCE
• Thyroid monitoring: TSH at baseline; no specific interval monitoring is required by the label, but women on levothyroxine may need dose adjustment as weight changes

Insurance and Access

Most commercial insurers and Medicare do not cover Wegovy for NASH. The listed price without insurance approaches $1,300 per month. Manufacturer savings programs (Novo Nordisk's NovoCare) may reduce cost for commercially insured patients, but uninsured or Medicaid patients face substantial access barriers. This is a real limitation and should be discussed with patients before prescribing.

How Semaglutide Compares to the Only FDA-Approved NASH Treatment

As of 2024, the FDA approved resmetirom (Rezdiffra) for NASH with moderate-to-advanced liver fibrosis (F2-F3). In the MAESTRO-NASH trial, resmetirom 100 mg achieved NASH resolution in 25.9% of patients at 52 weeks. The ESSENCE semaglutide result of 62.9% at 72 weeks is numerically higher, though these trials differ in duration, population, and methodology, making direct comparison unreliable. No head-to-head trial of semaglutide versus resmetirom has been published.

Resmetirom targets thyroid hormone receptor beta in the liver and has a specific hepatic mechanism not shared by semaglutide. Women with both NASH and significant obesity may achieve more weight-related benefit from semaglutide. Women with lean NASH, a less common phenotype, may find resmetirom more appropriate. Combination trials are ongoing.

What Comes Next: Regulatory Pathway

Novo Nordisk has submitted semaglutide 2.4 mg for FDA approval specifically in NASH based on ESSENCE data. A regulatory decision is anticipated in 2025. If approved, it would shift Wegovy from off-label to on-label for this indication and should substantially improve insurance coverage. Until then, off-label use requires explicit informed consent and individualized clinical judgment.